scholarly journals Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib

2021 ◽  
Author(s):  
Megumi Koshiishi ◽  
Toru Odate ◽  
Yukie Nakagawa ◽  
Jun Suzuki ◽  
Takuya Kumagai ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Hodgkin Lymphoma ◽  
Initial Treatment ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Leukemia Patient ◽  
Classic Hodgkin Lymphoma

Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient

2008 ◽  
Vol 32 (2) ◽  
pp. 363-365 ◽  
Author(s):  
Pasquale Niscola ◽  
Maria Ilaria Del Principe ◽  
Massimiliano Palombi ◽  
Stefano Fratoni ◽  
Daniela Piccioni ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Leukemia Patient ◽  
Cell Chronic Lymphocytic Leukemia

Doxorubicin and a butyric acid derivative effectively reduce levels of BCL-2 protein
in the cells of chronic lymphocytic
leukemia patient

2001 ◽  
Vol 66 (4) ◽  
pp. 263-271 ◽  
Author(s):  
E. Rabizadeh ◽  
O. Bairey ◽  
A. Aviram ◽  
I. Ben-Dror ◽  
M. Shaklai ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Acid Derivative ◽  
Butyric Acid ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Leukemia Patient

Chronic Lymphocytic Leukemia Patient Clustering Based on Somatic Hypermutation (SHM) Analysis

2017 ◽  
pp. 127-138 ◽  
Author(s):  
Eleftheria Polychronidou ◽  
Aliki Xochelli ◽  
Panagiotis Moschonas ◽  
Stavros Papadopoulos ◽  
Anastasia Hatzidimitriou ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Somatic Hypermutation ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Leukemia Patient

Composite Prolymphocytoid and Hodgkin Transformation of Chronic Lymphocytic Leukemia

2000 ◽  
Vol 124 (6) ◽  
pp. 907-909 ◽  
Author(s):  
Maureen J. O'Sullivan ◽  
Zahid Kaleem ◽  
Michael J. Bolger ◽  
Paul E. Swanson ◽  
Mary M. Zutter
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Hodgkin Lymphoma ◽  
Progressive Disease ◽  
Plasma Cells ◽  
Single Agent ◽  
Malignant Neoplasm ◽  
Lymphocytic Leukemia ◽  
Richter Syndrome ◽  
Classic Hodgkin Lymphoma ◽  
Single Agent Chemotherapy

Abstract The indolent course of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is occasionally altered by transformation to a histologically distinct, rapidly progressive, and clinically unresponsive hematologic malignant neoplasm. We report a case of CLL that, after 3 years of slowly progressive disease and treatment with single-agent chemotherapy (fludarabine phosphate), underwent a composite prolymphocytoid and classic Hodgkin lymphoma transformation. The diagnosis of classic Hodgkin lymphoma was based on the presence of Reed-Sternberg cells with typical morphologic structure and immunophenotype (CD15+, CD30+, CD45−, CD20−) associated with the characteristic polymorphous inflammatory background consisting of numerous eosinophils, plasma cells, and reactive T lymphocytes. The remainder of the lymph node and the peripheral blood showed increased numbers of prolymphocytes admixed with typical small CLL cells. Recognition of such a transformation is of the utmost importance, since histologically similar Reed-Sternberg–like cells may be seen in Richter transformation. In contrast to prolymphocytoid transformation of CLL, Richter syndrome is rapidly fatal, with a median survival of 4 to 5 months. The patient pursued a clinical course similar to pure prolymphocytoid transformation and died with disease after 30 months following treatment with combination chemotherapy.

Infected herpes zoster in a chronic lymphocytic leukemia patient treated with ibrutinib

2019 ◽  
Vol 85 ◽  
pp. S40 ◽  
Author(s):  
M. Okay ◽  
Y. Buyukasik ◽  
S. Aksu ◽  
I. Haznedaroglu ◽  
N. Sayinalp
Keyword(s):  
Herpes Zoster ◽  
Chronic Lymphocytic Leukemia ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Leukemia Patient

scholarly journals Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia

2019 ◽  
Vol 7 ◽  
pp. 2050313X1882391 ◽  
Author(s):  
Sharad Khurana ◽  
Salman Ahmed ◽  
Victoria R Alegria ◽  
Sonikpreet Aulakh ◽  
Meghna Ailawadhi ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Partial Remission ◽  
Single Agent ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Viable Option ◽  
Leukemia Patient ◽  
Therapeutic Landscape ◽  
Response Status ◽  
Anti Cd20

Obinutuzumab is used for the treatment of chronic lymphocytic leukemia. So far there are no data of using this for retreatment in patients who have received it previously. We introduced obinutuzumab for the retreatment in a chronic lymphocytic leukemia patient, who had first achieved partial remission with it and eventually relapsed over a course of 2.5 years. After retreatment with single-agent obinutuzumab, the patient achieved a partial remission again within one cycle and continues to maintain the response status. This case is a platform for considering obinutuzumab as a viable option for retreatment of chronic lymphocytic leukemia patients who have received it before, similar to the pattern of use for other anti-CD20 monoclonal antibodies in this disease, including rituximab.

Expression of a receptor for sheep erythrocytes by B lymphocytes from a chronic lymphocytic leukemia patient

1983 ◽  
Vol 27 (2) ◽  
pp. 210-222 ◽  
Author(s):  
Roberto Sitia ◽  
Luca Sciariada ◽  
Antonio Zicca ◽  
Arnaldo Leprini ◽  
Riccardo Ghio ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Lymphocytes ◽  
Chronic Lymphocytic Leukemia Patient ◽  
Lymphocytic Leukemia ◽  
Sheep Erythrocytes ◽  
Leukemia Patient
Sign in / Sign up

Export Citation Format

Share Document